"low-molecular-weight; meta-analysis"@en . . "RIV/61989592:15110/07:00004452" . "24" . . "The effect of low-molecular-weight heparin on cancer survival. A systemic review and meta-analysis of randomized trials."@en . "S" . . "Efekt n\u00EDzkomolekul\u00E1rn\u00EDho heparinu na p\u0159e\u017Eit\u00ED pacient\u016F s tumory - systematick\u00FD p\u0159ehled a metaanal\u00FDza randomizovan\u00FDch studi\u00ED" . "418759" . . . "1"^^ . "N\u00EDzkomolekul\u00E1rn\u00ED hepariny (LMWH) prok\u00E1zaly protin\u00E1dorov\u00E9 p\u016Fsoben\u00ED v in vitro studi\u00EDch a u experiment\u00E1ln\u00EDch malign\u00EDch anim\u00E1ln\u00EDch model\u016F. Retrospektivn\u00ED data nazna\u010Duj\u00ED, \u017Ee LMWH mohou zlep\u0161it p\u0159e\u017Eit\u00ED pacient\u016F s n\u00E1dorovou diagn\u00F3zou. Ji\u017E vminulosti \u0159ada studi\u00ED prok\u00E1zala bl\u00EDzk\u00FD vztah mezi faktory koagula\u010Dn\u00EDho syst\u00E9mu a rozvojem, diseminac\u00ED a progres\u00ED n\u00E1dorov\u00E9 chrooby. Tk\u00E1\u0148ov\u00FD faktor, fibrin a trombin podporuj\u00ED angiogenezi a spolu s plazminem posiluj\u00ED bun\u011B\u010Dnou migraci a sklon k metastazov\u00E1n\u00ED. Fibrin a trombocyty potla\u010Duj\u00ED protin\u00E1drov\u00E9 p\u016Fsoben\u00ED cytotoxick\u00FDch NK bun\u011Bk. Ovlivn\u011Bn\u00EDm kaogula\u010Dn\u00EDho syst\u00E9mu mohou m\u00EDt antikoagula\u010Dn\u00ED l\u00E9ky pozitivn\u00ED vliv na p\u0159e\u017Eit\u00ED paacient\u016F na z\u00E1klad\u011B n\u011Bkolika mechanizm\u016F - inhibic\u00ED proliferace malign\u00EDch bun\u011Bk, blok\u00E1dou angiogeneze, aktivnac\u00ED NK bun\u011Bk a potla\u010Den\u00EDm metastatick\u00FDch proces\u016F." . . "CZ - \u010Cesk\u00E1 republika" . "2"^^ . . "Low-molecular-weight heparins (LMWH) have an antitumor effect in vitro and in experimental animal models of malignancy. Retrospective data suggest that it might improve survival in cancer patients. Lazo-Langer et al. conducted a systematic review of randomized trials specifically evaluating the impact of LMWH on the survival of cancer patients. According to results LMWH improves overall survival in cancer patients, even in those with advanced disease. The results of the OR, RR and survival meta-analysis consistently favored the LMWH group. Sensitivity analyses according to tumor type were not conducted, because of a lack of information. Additional trials are required to define the tumor types, disease stages and dosing schedules most likely to provide the greatest survival benefit."@en . . "1" . . "1"^^ . "N\u00EDzkomolekul\u00E1rn\u00ED hepariny (LMWH) prok\u00E1zaly protin\u00E1dorov\u00E9 p\u016Fsoben\u00ED v in vitro studi\u00EDch a u experiment\u00E1ln\u00EDch malign\u00EDch anim\u00E1ln\u00EDch model\u016F. Retrospektivn\u00ED data nazna\u010Duj\u00ED, \u017Ee LMWH mohou zlep\u0161it p\u0159e\u017Eit\u00ED pacient\u016F s n\u00E1dorovou diagn\u00F3zou. Ji\u017E vminulosti \u0159ada studi\u00ED prok\u00E1zala bl\u00EDzk\u00FD vztah mezi faktory koagula\u010Dn\u00EDho syst\u00E9mu a rozvojem, diseminac\u00ED a progres\u00ED n\u00E1dorov\u00E9 chrooby. Tk\u00E1\u0148ov\u00FD faktor, fibrin a trombin podporuj\u00ED angiogenezi a spolu s plazminem posiluj\u00ED bun\u011B\u010Dnou migraci a sklon k metastazov\u00E1n\u00ED. Fibrin a trombocyty potla\u010Duj\u00ED protin\u00E1drov\u00E9 p\u016Fsoben\u00ED cytotoxick\u00FDch NK bun\u011Bk. Ovlivn\u011Bn\u00EDm kaogula\u010Dn\u00EDho syst\u00E9mu mohou m\u00EDt antikoagula\u010Dn\u00ED l\u00E9ky pozitivn\u00ED vliv na p\u0159e\u017Eit\u00ED paacient\u016F na z\u00E1klad\u011B n\u011Bkolika mechanizm\u016F - inhibic\u00ED proliferace malign\u00EDch bun\u011Bk, blok\u00E1dou angiogeneze, aktivnac\u00ED NK bun\u011Bk a potla\u010Den\u00EDm metastatick\u00FDch proces\u016F."@cs . "Efekt n\u00EDzkomolekul\u00E1rn\u00EDho heparinu na p\u0159e\u017Eit\u00ED pacient\u016F s tumory - systematick\u00FD p\u0159ehled a metaanal\u00FDza randomizovan\u00FDch studi\u00ED"@cs . "[F4178A759B3E]" . "RIV/61989592:15110/07:00004452!RIV08-MSM-15110___" . . . . "Efekt n\u00EDzkomolekul\u00E1rn\u00EDho heparinu na p\u0159e\u017Eit\u00ED pacient\u016F s tumory - systematick\u00FD p\u0159ehled a metaanal\u00FDza randomizovan\u00FDch studi\u00ED" . "15110" . . "Refer\u00E1tov\u00FD v\u00FDb\u011Br z onkologie" . "Efekt n\u00EDzkomolekul\u00E1rn\u00EDho heparinu na p\u0159e\u017Eit\u00ED pacient\u016F s tumory - systematick\u00FD p\u0159ehled a metaanal\u00FDza randomizovan\u00FDch studi\u00ED"@cs . "The effect of low-molecular-weight heparin on cancer survival. A systemic review and meta-analysis of randomized trials."@en . "62-63" . "0034-2815" . "Hlu\u0161\u00ED, Anton\u00EDn" .